Skip to content
10-Q

Quarterly Report

PHARMACEUTICAL PRODUCT DEVELOPMENT INC

0001193125-10-249246

← back to feed
Filed
Nov 5, 2010 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2010 · Oct 27, 2010 118.86M sh
Stockholders Equity Q3 2010 · Sep 30, 2010 $1.24B
Stockholders Equity Q3 2010 · Dec 31, 2009 $1.35B
Current Liabilities Q3 2010 · Sep 30, 2010 $588.16M
Current Liabilities Q3 2010 · Dec 31, 2009 $591.04M
Total Liabilities Q3 2010 · Sep 30, 2010 $664.9M
Total Liabilities Q3 2010 · Dec 31, 2009 $684.08M
Current Assets Q3 2010 · Sep 30, 2010 $1.07B
Current Assets Q3 2010 · Dec 31, 2009 $1.13B
Total Assets Q3 2010 · Sep 30, 2010 $1.91B
Total Assets Q3 2010 · Dec 31, 2009 $2.03B
Shares Diluted Q3 2010 · Sep 30, 2009 118.58M sh
Shares Diluted Q3 2010 · Sep 30, 2009 118.72M sh
Dividends Paid Q3 2010 · Sep 30, 2009 $50.18M
Capex Q3 2010 · Sep 30, 2009 $37.72M
Operating Cash Flow Q3 2010 · Sep 30, 2009 $137.11M
Cash And Equivalents Q3 2010 · Sep 30, 2009 $437.6M
Cash And Equivalents Q3 2010 · Dec 31, 2008 $491.76M
Eps Diluted Q3 2010 · Sep 30, 2009 $0.32
Eps Diluted Q3 2010 · Sep 30, 2009 $1.18
Eps Basic Q3 2010 · Sep 30, 2009 $0.32
Eps Basic Q3 2010 · Sep 30, 2009 $1.19
Rd Expense Q3 2010 · Sep 30, 2009 $974K
Rd Expense Q3 2010 · Sep 30, 2009 $3.26M
Net Income Q3 2010 · Sep 30, 2009 $37.67M
Net Income Q3 2010 · Sep 30, 2009 $140.3M
Operating Income Q3 2010 · Sep 30, 2009 $51.63M
Operating Income Q3 2010 · Sep 30, 2009 $176.48M
Revenue Q3 2010 · Sep 30, 2009 $340.4M
Revenue Q3 2010 · Sep 30, 2009 $1.06B